Published in Mov Disord on April 15, 2012
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol (2014) 1.12
Incident parkinsonism in older adults without Parkinson disease. Neurology (2016) 1.04
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One (2013) 1.03
Association of brain pathology with the progression of frailty in older adults. Neurology (2013) 1.01
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol (2014) 1.00
Household organophosphorus pesticide use and Parkinson's disease. Int J Epidemiol (2013) 0.98
Total daily activity declines more rapidly with increasing age in older adults. Arch Gerontol Geriatr (2013) 0.92
Parkinsonism in Older Adults and Its Association With Adverse Health Outcomes and Neuropathology. J Gerontol A Biol Sci Med Sci (2015) 0.91
Anxiety- and depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease. Front Behav Neurosci (2014) 0.86
The Progressive BSSG Rat Model of Parkinson's: Recapitulating Multiple Key Features of the Human Disease. PLoS One (2015) 0.86
Identifying the clusters within nonmotor manifestations in early Parkinson's disease by using unsupervised cluster analysis. PLoS One (2014) 0.85
The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res (2015) 0.84
Traffic-Related Air Pollution and Parkinson's Disease in Denmark: A Case-Control Study. Environ Health Perspect (2015) 0.83
Critical role of calpain in spinal cord degeneration in Parkinson's disease. J Neurochem (2013) 0.82
Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates. PLoS One (2014) 0.81
The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis (2015) 0.81
Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. Biochim Biophys Acta (2015) 0.79
Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One (2013) 0.79
Motor Sequence Learning and Consolidation in Unilateral De Novo Patients with Parkinson's Disease. PLoS One (2015) 0.76
Is there a need to redefine Parkinson's disease? J Neural Transm (Vienna) (2013) 0.76
Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis. Front Neurosci (2016) 0.75
Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments. Parkinsons Dis (2016) 0.75
Prodromal diagnosis of Parkinson's disease. Mov Disord (2012) 0.75
Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P T (2015) 0.75
Non-motor multiple system atrophy associated with sudden death: pathological observations of autonomic nuclei. J Neurol (2017) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol (2003) 5.00
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 3.79
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology (2008) 3.62
Frequency of bowel movements and the future risk of Parkinson's disease. Neurology (2001) 3.50
REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep (2002) 3.37
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett (2005) 3.30
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol (2010) 3.15
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA (2000) 2.89
Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol (2008) 2.73
Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology (1988) 2.72
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol (2005) 2.65
Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med (2011) 2.61
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology (2010) 2.50
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
When does Parkinson disease start? Arch Neurol (2010) 2.41
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry (1998) 2.24
Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord (2000) 2.20
Smoking and Parkinson's disease in twins. Neurology (2002) 2.15
Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology (1984) 2.08
Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc (2004) 2.00
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology (1999) 1.98
Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol (2002) 1.97
Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology (2003) 1.89
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord (2011) 1.87
The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol (1999) 1.85
The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol (2008) 1.80
Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet (1987) 1.77
Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology (1995) 1.77
Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet (1987) 1.75
Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One (2010) 1.72
Mild Parkinsonian signs: An overview of an emerging concept. Mov Disord (2007) 1.66
Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology (2005) 1.62
Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord (2003) 1.62
Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology (1987) 1.61
Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology (2007) 1.59
Midlife adiposity and the future risk of Parkinson's disease. Neurology (2002) 1.52
Prevalence of smell loss in Parkinson's disease--a multicenter study. Parkinsonism Relat Disord (2009) 1.50
Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol (2002) 1.45
Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord (2010) 1.42
Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet (1993) 1.42
Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology (1995) 1.40
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
Olfaction in neurodegenerative disorder. Mov Disord (2003) 1.36
At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. Am J Med Genet (1987) 1.34
Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord (2003) 1.33
Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology (2008) 1.32
Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology (1996) 1.30
Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol (2001) 1.27
Predictors of prognosis in patients with olfactory disturbance. Ann Neurol (2008) 1.25
Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci (1998) 1.25
[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology (1996) 1.24
Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm (Vienna) (2002) 1.21
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol (1994) 1.17
Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord (2001) 1.13
The preclinical detection of Parkinson's disease: ready for prime time? Ann Neurol (2004) 1.12
Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord (1997) 1.08
Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol (1997) 1.02
Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatry Clin Neurosci (1995) 1.01
Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol (1994) 1.00
REM sleep behaviour disorder differentiates pure autonomic failure from multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatry (1998) 0.98
Olfactory dysfunction as a diagnostic marker for Parkinson's disease. Expert Rev Neurother (2009) 0.95
A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients. Mov Disord (1995) 0.93
Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy. Parkinsonism Relat Disord (2007) 0.93
Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage (2003) 0.90
Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand (1998) 0.88
Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study. Mov Disord (2010) 0.88
Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord (2005) 0.86
Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology (1996) 0.85
Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology (2010) 0.84
Personality and depression in Parkinson's disease. J Nerv Ment Dis (1993) 0.83
Preclinical diagnosis of Parkinson's disease: are we there yet? Curr Neurol Neurosci Rep (2006) 0.83
Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord (2009) 0.79
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47
Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46
Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46
Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol (2002) 1.40
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38
Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol (2002) 1.36
Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol (2006) 1.34
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32
Gait abnormalities in psychogenic movement disorders. Mov Disord (2007) 1.32
Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol (2006) 1.31
Apraxia in movement disorders. Brain (2005) 1.29
The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet (2004) 1.29
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
The nonmotor symptoms of Parkinson's disease--an overview. Mov Disord (2010) 1.25
Movement disorders on YouTube--caveat spectator. N Engl J Med (2011) 1.25
The many faces of corticobasal degeneration. Parkinsonism Relat Disord (2007) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord (2003) 1.19
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol (2010) 1.16
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol (2004) 1.14
Pallidal neuronal activity: implications for models of dystonia. Ann Neurol (2003) 1.14
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14
Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. Hum Brain Mapp (2009) 1.13
Dystonia in complex regional pain syndrome type I. Ann Neurol (2010) 1.13
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord (2006) 1.13
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology (2003) 1.12
Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. Neurology (2003) 1.12